SARS-CoV-2 vaccine

22 April 2021

CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to Watson about the development of a next-generation SARS-CoV-2 vaccine, RVX-13

“There is light at the end of the tunnel. Progress is being made in vaccines against SARS-CoV-2, if somewhat slowly, particularly in Switzerland. They promise a return to normality, though they are not without setbacks. The vector vaccines developed by AstraZeneca and Johnson & Johnson are under fire following cases of thrombosis in younger women.

The mutated virus strains are also a source of concern. They may be able to circumvent the immune defences constructed by the vaccines currently being administered, which is why it is considered almost certain that regular boosters will be needed in the future. How wonderful it would be if a vaccine existed that could solve the problem once and for all.

One man believes that he can provide this: Vladimir Cmiljanović and his Basel-based company RocketVax are attempting to develop a second-generation corona vaccine “for Switzerland and for the entire world”. It is intended to have longer-term efficacy and provide permanent protection, “regardless of mutations”, as Cmiljanović explained in an interview with Watson.

‘The goal is not just to fight the current pandemic, but also future pandemics,’ said Cmiljanović. These sound like the words of a megalomaniac, but the 41-year-old is entirely serious. He emphasises that intensive work has been ongoing over the last eight months. He was clearly able to convince the Swiss government, as he is reporting initial successes.”

To read the full article (EN or DE), click on the files below:

Watson RocketVax EN                                    Watson RocketVax DE


21 April 2021

CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to SRF 1 radio about next generation SARS-CoV-2 vaccine, RVX-13

Dr. Vladimir Cmiljanovic, CEO of RocketVax, gave an interview to Swiss SRF 1 radio about the progress of RVX-13 – a second-generation SARS-CoV-2 vaccine: Source: SRF 1 Radio The most important differences between RVX-13, RocketVax’s SARS-CoV-2 vaccine, and the first-generation vaccines are as follows: 1. RVX-13 induces a comprehensive activation of the immune system. Unlike […]

20 April 2021

Serbian “Telegraf” is reporting about RocketVax’s SARS-CoV-2 vaccine

When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working […]

09 April 2021

How come China controls the pandemic so effectively? How will the second-generation of SARS-CoV-2 vaccine, RVX-13, provide long-lasting immunity?

CEO of RocketVax, Dr. Vladimir Cmiljanovic, explains for Kanal 5 TV Macedonia his opinion on how China has managed to control the pandemic rapidly and effectively. During the interview, Dr. Cmiljanovic also talked about the development of the second-generation SARS-CoV-2 vaccine, RVX-13, that will provide long-lasting immunity. “The first reason is that the socialist system […]

16 March 2021

Dr. Vladimir Cmiljanovic: “RocketVax SARS-CoV-2 vaccine should be effective regardless of the mutation occurring on the spike protein”

CEO of RocketVax, Dr. Vladimir Cmiljanovic, gave an interview about the development of the second-generation SARS-CoV-2 vaccine for RTS (Serbian Broadcasting Corporation). “The first-generation vaccines are focused on one of the virus’s proteins – the so-called spike protein. They train our immune system by exposing the coronavirus spike protein to our immune cells. The so […]

09 February 2021

CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to K1 TV about next generation SARS-CoV-2 vaccine, RVX-13

The Rocket Vaccine against the coronavirus will be the most effective in the defense against this vicious disease because it is the only one containing the actual, synthetically generated virus. A team of experts from Switzerland, led by Dr. Vladimir Cmiljanovic, deserves credit for that invention. What is the progress of the clinical trials? When […]